Superworth

AbbVie forward PE ABBV

Share price divided by analysts' consensus earnings for the next twelve months, since 2012.

Today, Nov 3, 2026
18.3×
10-year median
12.2×
Against its 10-year history
87th
percentile: 0 is its lowest day, 100 its highest
10-year range
6.8× to 22.3×
Peer median
19.8×

AbbVie's forward PE is 18.3× as of Nov 3, 2026.

That is above its ten-year median of 12.2×, higher than on 87% of days in the last ten years.

Over that time it ranged from 6.8× in Mar 2020 to 22.3× in Nov 2024.

The median for 7 large drugmakers of a similar size is 19.8×.

Forward PE over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far18.3×13.7×19.4×
202518.3×17.4×22.1×
202419.5×15.4×22.3×
202314.7×12.3×14.8×
202213.7×9.9×13.9×
202110.2×8.2×10.2×
20209.0×6.8×9.8×
20199.5×7.2×10.5×
201810.7×9.8×17.7×
201713.9×10.9×15.0×
201612.1×10.8×13.9×
201513.0×11.5×18.0×
201418.3×16.0×19.8×
201318.6×11.4×18.6×
201211.6×11.1×11.9×

Against its peers

Companies in Drug Manufacturers - General nearest AbbVie's size, closest first, today.

CompanyForward PE
ABBVAbbVie18.3×
JNJJohnson & Johnson23.9×
MRKMerck17.2×
AMGNAmgen19.8×
GILDGilead Sciences19.8×
LLYEli Lilly and30.9×
PFEPfizer11.2×
BMYBristol-Myers Squibb9.8×
Peer median19.8×

Where AbbVie ranks

What the forward PE tells you

Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.

Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.

More on AbbVie

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.